Keywords: ThromboGenics, BioInvent, Roche, TB-403, Retinal diseases, TB-402, Anticoagulant, Bayer, Xarelto
Roche returns rights to TB-403 to ThromboGenics and BioInvent, who abandon TB-402 development
Article | 05 June 2012
Belgium-based biopharma company ThromboGenics NV (Euronext Brussels: THR) and co-development partner Sweden’s BioInvent International (OMXS: BINV) announced this ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
